company background image
4551 logo

Torii Pharmaceutical TSE:4551 Stock Report

Last Price

JP¥3.62k

Market Cap

JP¥102.5b

7D

-2.2%

1Y

0.1%

Updated

13 Jun, 2024

Data

Company Financials +

Torii Pharmaceutical Co., Ltd.

TSE:4551 Stock Report

Market Cap: JP¥102.5b

4551 Stock Overview

Manufactures and markets pharmaceutical products in Japan.

4551 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends1/6

Torii Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Torii Pharmaceutical
Historical stock prices
Current Share PriceJP¥3,615.00
52 Week HighJP¥4,370.00
52 Week LowJP¥3,415.00
Beta0.36
1 Month Change-8.02%
3 Month Change-14.54%
1 Year Change0.14%
3 Year Change45.47%
5 Year Change35.09%
Change since IPO-1.78%

Recent News & Updates

Recent updates

Shareholder Returns

4551JP PharmaceuticalsJP Market
7D-2.2%-0.7%0.3%
1Y0.1%-0.7%17.5%

Return vs Industry: 4551 matched the JP Pharmaceuticals industry which returned -0.7% over the past year.

Return vs Market: 4551 underperformed the JP Market which returned 17.5% over the past year.

Price Volatility

Is 4551's price volatile compared to industry and market?
4551 volatility
4551 Average Weekly Movement3.0%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement3.9%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4551 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4551's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1872583Goichi Matsudawww.torii.co.jp

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE.

Torii Pharmaceutical Co., Ltd. Fundamentals Summary

How do Torii Pharmaceutical's earnings and revenue compare to its market cap?
4551 fundamental statistics
Market capJP¥102.47b
Earnings (TTM)JP¥5.29b
Revenue (TTM)JP¥56.28b

19.2x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4551 income statement (TTM)
RevenueJP¥56.28b
Cost of RevenueJP¥33.08b
Gross ProfitJP¥23.20b
Other ExpensesJP¥17.91b
EarningsJP¥5.29b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 31, 2024

Earnings per share (EPS)188.26
Gross Margin41.22%
Net Profit Margin9.39%
Debt/Equity Ratio0%

How did 4551 perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

n/a

Payout Ratio

Does 4551 pay a reliable dividends?

See 4551 dividend history and benchmarks
When do you need to buy 4551 by to receive an upcoming dividend?
Torii Pharmaceutical dividend dates
Ex Dividend DateJun 27 2024
Dividend Pay DateSep 05 2024
Days until Ex dividend14 days
Days until Dividend pay date84 days

Does 4551 pay a reliable dividends?

See 4551 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.